APOE ɛ4, an Alzheimer's disease susceptibility allele, and smoking cessation [0.03%]
载脂蛋白ε4型等位基因与吸烟 cessation的关系
R L Ashare,J H Karlawish,E P Wileyto et al.
R L Ashare et al.
Possessing an apolipoprotein E (APOE) ɛ4 allele, advanced age and smoking are risk factors for Alzheimer's disease and cognitive decline. Deficits in cognitive function also increase risk for smoking relapse. Data from 917 adult smokers of...
Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation [0.03%]
多民族细胞色素P450拷贝数谱分析：新的药物基因组学等位基因和拷贝数变异形成机制
S Martis,H Mei,R Vijzelaar et al.
S Martis et al.
To determine the role of CYP450 copy number variation (CNV) beyond CYP2D6, 11 CYP450 genes were interrogated by multiplex ligation-dependent probe amplification and quantitative PCR in 542 African-American, Asian, Caucasian, Hispanic and As...
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients [0.03%]
FMO1和FMO3多态性对精神病患者血清奥氮平及其N-氧化代谢物浓度的影响
M M Söderberg,T Haslemo,E Molden et al.
M M Söderberg et al.
The widely used antipsychotic drug, olanzapine (OLA) shows large interindividual variability in metabolic clearance. Although the role of the enzymes CYP1A2, CYP2D6 and UGT1A4 has been extensively explored, little is known about the in vivo...
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients [0.03%]
HIV患者中依非韦伦诱导CYP3A的药代动力学和药物基因组学研究
A Habtewold,W Amogne,E Makonnen et al.
A Habtewold et al.
We investigated the effects of pharmacogenetic variations and efavirenz pharmacokinetics on inter-individual differences in the extent of CYP3A induction by efavirenz using 4β-hydroxycholesterol/cholesterol (4β-OHC/Chol) as a marker for C...
Multicenter Study
The pharmacogenomics journal. 2013 Dec;13(6):484-9. DOI:10.1038/tpj.2012.46 2013
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects [0.03%]
药物代谢酶的药理基因组学：近期关于临床应用和内源性效应的更新内容
S C Sim,M Kacevska,M Ingelman-Sundberg
S C Sim
Interindividual differences in drug disposition are important causes for adverse drug reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing enzymes (DMEs) are polymorphic and constitute essential factor...
A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia [0.03%]
叶酸代谢关键酶基因多态性预测甲氨喋呤毒性反应的系统评价和meta分析
E Lopez-Lopez,I Martin-Guerrero,J Ballesteros et al.
E Lopez-Lopez et al.
Methotrexate (MTX) is an important component of therapy used to treat childhood acute lymphoblastic leukemia (ALL). Two single-nucleotide polymorphisms (SNPs) in the methylenetetrahydrofolate reductase (MTHFR) gene, C677T and A1298C, affect...
Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy [0.03%]
ABCC2多态性对淋巴瘤患者大剂量甲氨蝶呤药代动力学的影响分析
N Simon,A Marsot,E Villard et al.
N Simon et al.
Human multidrug resistance-related protein 2 (MRP2, encoded by ABCC2) is involved in the transport of anionic drugs such as methotrexate (MTX). We prospectively investigated the influence of four common ABCC2 genetic variants (rs717620, rs2...
J E Wyatt,W L Pettit,S Harirforoosh
J E Wyatt
With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacother...
Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications [0.03%]
II相代谢酶和药物转运体的药物基因组学及其临床意义
E Ch Yiannakopoulou
E Ch Yiannakopoulou
The clinical impact of pharmacogenomics remains a hot topic of current research efforts. Although pharmacogenomics of phase I metabolizing enzymes seems to have been well studied, knowledge on the clinical impact of genetic variability of p...
Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies [0.03%]
多发性硬化症的药物基因组学更新：实际和新治疗策略的重点
V Foti Cuzzola,E Palella,D Celi et al.
V Foti Cuzzola et al.
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of central nervous system comprising several subtypes. Pharmacological treatment involves only few drugs. Among these, interferon beta (IFN-β) and glatiramer acetate were...